Filgotinib not checked
Alfasigma S.p.A. · GS-6034 · GLPG0634
FollowEvery change as it happens, and a Monday email
Trials
12 active
18 in total · 18 in the EU
What this is
- How it works
- Blocks JAK enzymes that pass on immune signals, to calm an overactive immune system.JAK inhibitor Named by hand
- How it’s given
- “IP will be provided as commercially developed film-coated tablets or age-appropriate film- coated tablets for use in paediatric subjects aged at least 8 years and needs to be taken orally q.d. at approximately the same time every morning (with or without food)”In the company’s words, NCT07554495 on ClinicalTrials.gov
- Tested for
- Axial Spondyloarthritis, Polyarticular Course Juvenile Idiopathic Arthritis, Juvenile Idiopathic Arthritis (JIA), Ulcerative Colitis
- Main trialPhase 3
- “This study is comparing 200 milligrams (mg) of filgotinib a day with a placebo to see if filgotinib helps to treat Axial Spondyloarthritis (axSpA) and is safe to use. The study will also be comparing 200 mg with 100 mg filgotinib a day to see if the lower dose also helps to treat axSpA.”In the company’s words, NCT05785611 on ClinicalTrials.gov
- Other names
- GS-6034 · GLPG0634 · Jyseleca
Other drugs for Axial Spondyloarthritis
- LNK01001Lynk Pharmaceuticals Co., Ltd · Phase 3
- JitongningTasly · Phase 3
- 6083SBio · Phase 3
- BCD-180Biocad · Phase 3
- HS_SW01 cellsShenzhen Huishan Biotechnology Co., Ltd. · Phase 1/2
- VilamakitugXBiotech, Inc. · Phase 2
Coming up3
- Jun 2027Phase 3 trial completes · ClinicalTrials.gov
- Dec 2027Phase 3 trial completes · ClinicalTrials.gov
- Jun 2028Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials18
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | 4 Sep 2024 | A Study Evaluating the Effect of Filgotinib in Participants With Active Axial Spondyloarthritis | |
| Phase 3Recruiting | Jun 2027 | Safety, Tolerability, Pharmacokinetics, and Efficacy of Filgotinib for the Treatment of Polyarticular-course Juvenile Idiopathic Arthritis in Children and Adolescents | |
| Phase 3Recruiting | Dec 2027 | OLE Study With Filgotinib in JIA | |
| Phase 3Recruiting | Jun 2028 | A Study Evaluating the Effects of Filgotinib in Children and Teenagers With Ulcerative Colitis | |
| Phase 3Completed | 16 May 2025 | Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Adults With Rheumatoid Arthritis | |
| Phase 3Completed | 8 Sep 2026 | Filgotinib in Long-Term Extension Study of Adults With Ulcerative Colitis | |
| Phase 1Terminated | 17 Jun 2026 | Study to Measure Filgotinib in the Blood of Children and Teenagers With Arthritis Taking Filgotinib (SCALESIA) | |
| Phase 2Not authorised | not given | Drug Rediscovery for rare Immune Mediated Inflammatory Diseases (DRIMID) | |
| Phase 2Authorised | not given | Drug Rediscovery for rare Immune Mediated Inflammatory Diseases (DRIMID) | |
| Phase 4Authorised | not given | JAK inhibitor dose TAPering strategy study in low disease activity rheumatoid arthritis patients | |
| Phase 4Ended | not given | PeRsonalIzed MEdicine in Rheumatoid Arthritis (PRIMERA trial): a multicenter, open-label, randomized controlled trial comparing usual care with a tailor-made approach | |
| Phase 3Authorised | not given | FirST lines of biologics in pAtients with ulceRaTivE colitis: a Randomised controlled trial | |
| Phase 3/4Authorised | not given | RANDOMIZED CONTROLLED CLINICAL TRIAL EVALUATING METHOTREXATE OR LEFLUNOMIDE + TARGETED THERAPY VERSUS METHOTREXATE OR LEFLUNOMIDE + SULFASALAZINE + HYDROXYCHLOROQUINE IN PATIENTS WITH RHEUMATOID ARTHRITIS AND INSUFFICIENT RESPONSE TO METHOTREXATE OR LEFLUNOMIDE (The BIO-3 trial) | |
| Phase 4Authorised | not given | Filgotinib bridging in newly diagnosed rheumatoid arthritis patients (FAST RA trial); A pragmatic randomized controlled non-inferiority low intervention clinical trial | |
| Phase 4Ended | not given | The effect of Janus Kinase inhibitors on the heart in Rheumatoid Arthrtis | |
| Phase 4Authorised | not given | REDO-JAK: Dose REDuction Of JAnus Kinase inhibitors in patients with inflammatory rheumatic diseases | |
| Phase 4Authorised | not given | Optimising Arthritis Strategies in Elderly patients (≥70 years) with rheumatoid arthritis in sustained low disease activity (the OASE study): A Prospective Target Trial Emulation Study Evaluating Tapering of Disease-Modifying Anti-Rheumatic Drugs vs. Usual Care Based on Patient Preference | |
| Phase 4Authorised | not given | STOP - Safety and efficacy of a STOPping strategy versus classical maintenance dose of JAK inhibitors in deep remission patients with ulcerative colitis: a randomized controlled trial |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026